Trending

her2

EMA starts review of Enhertu for HER2+ gastric cancer

EMA starts review of Enhertu for HER2+ gastric cancer

The EMA has started its review of AstraZeneca and Daiichi Sankyo’s Enhertu for a second indication, as a

X

EMA starts review of Enhertu for HER2+ gastric cancer

https://pharmaphorum.com/news/ema-starts-review-of-enhertu-for-her2-gastric-cancer/

Seagen’s breast cancer drug Tukysa turned down by NICE

Seagen’s breast cancer drug Tukysa turned down by NICE

NICE has decided not to recommend Seagen’s orally-active HER2 inhibitor Tukysa for advanced breast cancer in draft guidance,

X

Seagen’s breast cancer drug Tukysa turned down by NICE

https://pharmaphorum.com/news/seagens-breast-cancer-drug-tukysa-turned-down-by-nice/

HER2 heats up as Seagen licenses RemeGen ADC for $2.6bn

HER2 heats up as Seagen licenses RemeGen ADC for $2.6bn

Seagen is a specialist in antibody-drug conjugates, but has looked to Chinese biotech RemeGen for a HER2-targeting candidate

X

HER2 heats up as Seagen licenses RemeGen ADC for $2.6bn

https://pharmaphorum.com/news/her2-heats-up-as-seagen-licenses-remegen-adc-for-2-6bn/

Ambrx tries another IPO as it chases down HER2 rivals

Ambrx tries another IPO as it chases down HER2 rivals

California biotech Ambrx Biopharma is hoping to raise $126 million from a listing on the New York Stock

X

Ambrx tries another IPO as it chases down HER2 rivals

https://pharmaphorum.com/news/ambrx-tries-another-ipo-as-it-chases-down-her2-rivals/

ASCO data back AZ/Daiichi Sankyo’s Enhertu in new HER2 cancers

ASCO data back AZ/Daiichi Sankyo’s Enhertu in new HER2 cancers

With an FDA approval for HER2-positive breast cancer already in the bag, Daiichi Sankyo and AstraZeneca’s Enhertu now

X

ASCO data back AZ/Daiichi Sankyo’s Enhertu in new HER2 cancers

https://pharmaphorum.com/news/asco-2020-astrazeneca-enhertu-cancer/

FDA sets August action date for Seattle’s oral HER2 drug tucatinib

FDA sets August action date for Seattle’s oral HER2 drug tucatinib

Seattle Genetics is a few months away from having its third drug product on the market, after the

X

FDA sets August action date for Seattle’s oral HER2 drug tucatinib

https://pharmaphorum.com/news/fda-sets-august-action-date-for-seattles-oral-her2-drug-tucatinib/

Exclusive Pfizer Speaker Interview Released

Exclusive Pfizer Speaker Interview Released

Exclusive Pfizer Speaker Interview Released

X

Exclusive Pfizer Speaker Interview Released

https://pharmaphorum.com/partner-content-oncology/exclusive-pfizer-speaker-interview-released/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com